Showing results (81-90 of 147) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupAgop Y Bedikian, Michael Millward, Hubert Pehamberger, et al.
Thyroid : Official Journal of the American Thyroid Association|October 7, 2014
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerGerald S Falchook, Michael Millward, David Hong, et al.
Future Oncology (London, England)|July 30, 2019
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancerRachel Woodford, Yanni Loh, Joanna Lee, et al.
Pathology|November 1, 2019
Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancerNick Pavlakis, Caroline Cooper, Thomas John, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)Giuseppe Giaccone, Channa Debruyne, Enriqueta Felip, et al.
Oncotarget|October 6, 2017
Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic deviceCarlos A Aya-Bonilla, Gabriela Marsavela, James B Freeman, et al.
The Oncologist|March 13, 2020
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot StudyMuhammad A Khattak, Anna Reid, James Freeman, et al.
British Journal of Cancer|February 11, 2020
Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cellsCarlos Alberto Aya-Bonilla, Michael Morici, Xin Hong, et al.
Investigational New Drugs|October 6, 2006
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanomaRichard Kefford, Jane McNeil Beith, Guy Arthur Van Hazel, et al.
Chest|March 13, 2012
Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusionEdward T H Fysh, Grant W Waterer, Peter A Kendall, et al.
Pageof 15